We are monitoring the impact of COVID-19 & Recession alarm on MEA Uterine Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Uterine Cancer Therapeutics Market Research Report – Segmented By Type, Therapy, Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends, Forecasts (2022 to 2027)

Published: January, 2022
ID: 1415
Pages: 133

MEA Uterine Cancer Therapeutics Market Size (2022 to 2027)

The Uterine Cancer Therapeutics Market size in the Middle East & Africa is expected to reach USD 1.03 Billion by 2027 from USD 0.79 Billion in 2020, growing at a CAGR of 5.40% during the forecast period.

The Uterine Cancer Therapeutics Market in the MEA region is expected to be driven by the rising number of uterine cancer population, growing awareness among people about uterine therapies, and increasing demand for advanced therapies are driving the market growth. In addition, an increase in cases of women being diagnosed with uterine cancer across the region is influencing the market growth. Furthermore, increasing risk factors leading to cancer is one of the major factors driving the market growth. In addition, the rising importance of targeted diseases is also surging the market growth. 

Moreover, technological advancements in uterine cancer therapeutics provide lucrative opportunities for the market players to introduce new products. In addition, increasing investment and funding by the government and private organizations to develop novel drugs to treat cancer is expanding the market growth. 

In addition, increasing healthcare expenditure, growing advancements in cancer screening & treatment methods, and the rising focus of government to provide adequate healthcare services are augmenting the market growth. 

In South Africa, the Cancer Association of South Africa (CANSA) is an organization that offers integrated services to the people affected by cancer in the country. Its purpose includes conducting cancer-prevention research, educating the public about symptoms, screening and risk reduction, and providing treatment and support to all cancer patients. In addition, the South African Department of Health launched initiatives to promote women's health, and all of these programs are projected to boost early diagnosis procedures in the near future.

However, the low success rate of cancer drug clinical trials, expensive treatment techniques, terrible side effects, and high toxicity of these drugs are all expected to restricting the MEA regional market growth in uterine cancer therapy and diagnosis.

This research report on the MEA Uterine Cancer Therapeutics Market is segmented & sub-segmented into the following categories:

By Type:

  • Uterine Sarcoma
  • Endometrial Carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Others

By Therapy:

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Hormone Therapy

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The MEA Uterine Cancer Therapeutics Market is projected to witness a promising share during the forecast period due to the increasing incidence of diseases and a growing number of women diagnosed with uterine cancer in the region. Developing countries such as Saudi Arabia, South Africa, and UAE contribute to the development of regional cancer centers. Over the forecast period, South Africa and UEA accounted significant share in the Uterine cancer therapeutics market. Increasing obesity among women is thought to be the primary cause of the rise in endometrial cancer cases. With the rising prevalence of the condition and increased awareness of it, it is expected that the segment will develop rapidly in the near future.

According to the National Clinical Trials (NCT) Registry, the "ASPIRE" clinical study for the treatment of endometrial cancer with stereotactic ablative radiation (SABR/SBRT) therapy is in phase II development in Saudi Arabia as of June 18, 2020. If the study results in a favorable conclusion, the market will be boosted in the near future since new therapies are planned in the coming years. Therefore, due to these activities and research efforts, the region's market is projected to grow in the future.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the MEA Uterine Cancer Therapeutics market profiled in this report are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH and Takeda Pharmaceutical Company Ltd.

1.Introduction               

                1.1 Market Definition 

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods        

                1.4 General Study Assumptions                

2. Research Methodology     

                2.1 Introduction           

                2.2 Research Phases   

             2.2.1 Secondary Research            

             2.2.2 Primary Research 

             2.2.3 Econometric Modelling     

             2.2.4 Expert Validation  

                2.3 Analysis Design      

                2.4 Study Timeline       

3. Overview

                3.1 Executive Summary                

                3.2 Key Inferences      

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers       

                4.2 Market Restraints 

                4.3 Key Challenges      

                4.4 Current Opportunities in the Market               

5. Market Segmentation        

                5.1 By Type     

             5.1.1 Endometrial Carcinoma     

          5.1.2.1 Adenocarcinoma

          5.1.2.2 Carcinosarcoma

          5.1.2.3 Squamous cell carcinoma

          5.1.2.4 Others

             5.1.2 Uterine Sarcoma  

                5.2 By Therapy                 

             5.2.1 Surgery    

             5.2.2 Chemotherapy     

             5.2.3 Radiation Therapy

             5.2.4 Immunotherapy   

             5.2.5 Hormone Therapy

6. Geographical Analysis        

                6.1 Introduction           

                6.2 Middle-East             

                6.3 Africa         

7. Pipeline Product Analysis  

                7.1 Overview 

                7.2 Pipeline Development Landscape  

                7.3 Molecular Targets in the Pipeline   

                7.4 Clinical Trials           

             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis  

                8.1 PESTLE analysis      

             8.1.1 Political     

             8.1.2 Economic 

             8.1.3 Social         

             8.1.4 Technological         

             8.1.5 Legal          

             8.1.6 Environmental      

                8.2 Porter’s Five analysis           

             8.2.1 Bargaining Power of Suppliers        

             8.2.2 Bargaining Power of Consumers    

             8.2.3 Threat of New Entrants     

             8.2.4 Threat of Substitute Products and Services

             8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis    

                9.1 Abbott Laboratories (U.S.)

             9.1.1 Overview

             9.1.2 Product Analysis   

             9.1.3 Financial analysis  

             9.1.4 Recent Developments       

             9.1.5 SWOT analysis       

             9.1.6 Analyst View          

                9.2 Ariad Pharmaceuticals, Inc. (U.S.)  

                9.3 Becton, Dickinson and Company (U.S.)        

                9.4 F. Hoffmann-La Roche AG (Switzerland)     

                9.5 GlaxoSmithKline Plc (U.K.)

                9.6 Merck & Co., Inc. (U.S.)      

                9.7 Novartis AG (Switzerland) 

                9.8 Sanofi (France)      

                9.9 Siemens Healthcare GmbH (Germany)        

                9.10 Takeda Pharmaceutical Company Ltd. (Japan)       

10.Competitive Landscape    

                10.1 Market share analysis       

                10.2 Merger and Acquisition Analysis  

                10.3 Agreements, collaborations and Joint Ventures    

                10.4 New Product Launches    

11.Market Outlook & Investment Opportunities            

Appendix     

                a) List of Tables                

                b) List of Figures           

  1. Middle East & Africa Uterine Cancer Therapeutics Market. By Region, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Uterine Cancer Therapeutics Market. By Type, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Endometrial Carcinoma Market. By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa Uterine Sarcoma Market. By Region, From 2022 - 2027 (USD Billion)
  5. Middle East & Africa Uterine Cancer Therapeutics Market. By Therapy, From 2022 - 2027 (USD Billion)
  6. Middle East & Africa Uterine Cancer Surgery Market. By Region, From 2022 - 2027 (USD Billion)
  7. Middle East & Africa Uterine Cancer Chemotherapy Market. By Region, From 2022 - 2027 (USD Billion)
  8. Middle East & Africa Uterine Cancer Immunotherapy Market. By Region, From 2022 - 2027 (USD Billion)
  9. Middle East & Africa Uterine Cancer Radiation Therapy Market. By Region, From 2022 - 2027 (USD Billion)
  10. Middle East & Africa Uterine Cancer Hormone Therapy Market. By Region, From 2022 - 2027 (USD Billion)
  11. Middle-East Uterine Cancer Therapeutics Market. By Type, From 2022 - 2027 (USD Billion)
  12. Middle-East Uterine Cancer Therapeutics Market. By Therapy, From 2022 - 2027 (USD Billion)
  13. Africa Uterine Cancer Therapeutics Market. By Type, From 2022 - 2027 (USD Billion)
  14. Africa Uterine Cancer Therapeutics Market. By Therapy, From 2022 - 2027 (USD Billion)
  15. Middle East & Africa Endometrial Carcinoma Market. By Type, From 2022 - 2027 (USD Billion)
  16. Middle East & Africa Adenocarcinoma Market. By Region, From 2022 - 2027 (USD Billion)
  17. Middle East & Africa Carcinosarcoma Market. By Region, From 2022 - 2027 (USD Billion)
  18. Middle East & Africa Squamous cell carcinoma Market. By Region, From 2022 - 2027 (USD Billion)
  19. Middle East & Africa Other Endometrial Carcinoma Market. By Region, From 2022 - 2027 (USD Billion)
  20. Middle-East Endometrial Carcinoma Market. By Type, From 2022 - 2027 (USD Billion)
  21. Africa Endometrial Carcinoma Market. By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample